In part 1 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about his work at Novo Nordisk not only as chief medical officer but also as a person with type 1.
Read More »Daily Archives: Sep 22, 2017
Todd Hobbs Part 2, Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine
In part 2 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about DEVOTE data and how degludec works.
Read More »Todd Hobbs Part 3, Dual 7 Trial-Xultophy
In part 3 of this Exclusive Interview, Dr. Todd Hobbs explains the DUAL-7 data in a converstion with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.
Read More »Todd Hobbs Part 4, GLP-1 Drug Trials
In part 4 of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about the GLP-1 cardiovascular trials and the significance of the LEADER study.
Read More »Todd Hobbs Part 5, The Future of Novo Nordisk
In part 5, the conclusion, of this Exclusive Interview, Dr. Todd Hobbs talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about what's in the pipeline for Novo Nordisk and smart insulin.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.